SCHEMBL508302

SCHEMBL508302

C=CCc1cccc(C(=O)c2ccccc2)c1O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.53
GABRB2 P47870 1/20 0.53
KDM4E B2RXH2 4/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
HTT P42858 3/20 0.46
KMT2A Q03164 3/20 0.46
AKR1C3 P42330 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.43
ALOX12 P18054 1/20 0.43
ELANE P08246 1/20 0.43
AKR1B1 P15121 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680147 0.89 GABRA1 (0.61) GABRA1GABRB2KDM4EMAPTMEN1
SCHEMBL30560007 0.87 AKR1C3 (0.50) GABRA1GABRB2KDM4EMAPTAKR1C3
SCHEMBL170063 0.87 AKR1C3 (0.50) GABRA1GABRB2KDM4EMAPTAKR1C3
SCHEMBL943893 0.87 AKR1C3 (0.50) GABRA1GABRB2KDM4EMAPTAKR1C3
SCHEMBL11854227 0.87 GABRA1 (0.49) GABRA1GABRB2KDM4EMAPTMEN1
Ammonia Solution, Strong SCHEMBL28897507 0.85 AKR1C3 (0.48) GABRA1GABRB2KDM4EMAPTAKR1C3
Ethylene SCHEMBL11742925 0.85 AKR1C3 (0.48) GABRA1GABRB2KDM4EMAPTAKR1C3
SCHEMBL474923 0.84 AKR1C3 (0.44) GABRA1GABRB2KDM4EMAPTMEN1
SCHEMBL9502265 0.84 GABRA1 (0.49) GABRA1GABRB2KDM4EMAPTMEN1
SCHEMBL40309 0.83 GABRA1 (0.59) GABRA1GABRB2KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116195582-A Stable cyclohexanedione oxime compositions 安道麦阿甘有限公司 2023-06-02 CN claimed
CN-116158426-A Stable cyclohexanedione oxime compositions 安道麦阿甘有限公司 2023-05-26 CN claimed
CN-111712523-B Ophthalmic product composition 爱尔兰眼力健公司 2023-01-03 CN claimed
EP-3728339-B1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS AMO Ireland (IE) 2022-07-06 EP claimed
US-11359031-B2 Composition for ophthalmological products Johnson & Johnson Surgical Vision, Inc. (US) 2022-06-14 US claimed
EP-3728339-A1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS Merck Patent GmbH (DE) 2020-10-28 EP claimed
US-20200332041-A1 COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS MERCK PATENT GMBH (DE) 2020-10-22 US claimed
CN-111712523-A Ophthalmic product composition 默克专利股份有限公司 2020-09-25 CN claimed
CN-104871036-B Method for making improved UV-absorbing ophthalmic lenses 诺华股份有限公司 2019-12-10 CN claimed
EP-3542193-A1 METHOD FOR MAKING OPHTHALMIC LENSES Novartis AG (CH) 2019-09-25 EP claimed
US-20130095235-A1 METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES NOVARTIS AG (CH) 2013-04-18 US claimed
WO-2013055746-A1 METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES BY COATING NOVARTIS AG (CH) 2013-04-18 WO claimed
US-8383744-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2013-02-26 US claimed
CN-101960388-B Semiconductor surface treatment agent composition and method for treating semiconductor surface using the same WAKO PURE CHEM IND LTD 2012-11-28 CN claimed
EP-2480927-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES Novartis AG (CH) 2012-08-01 EP claimed
EP-2432808-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS Novartis AG (CH) 2012-03-28 EP claimed
WO-2011034801-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES NOVARTIS AG (CH) 2011-03-24 WO claimed
US-20110063567-A1 PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES ALCON INC. (CH) 2011-03-17 US claimed
WO-2010133680-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2010-11-25 WO claimed
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS ALCON INC. (CH) 2010-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS VCL, MACF1, CFL1 GABRA1 832/4885GABRB2 1644/4885KDM4E 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.